CAS: 5868-05-3; Niceritrol

该化合物是一个化学化合物,属于尼古丁酸衍生物类别,主要因其作为脂质调控剂的作用而得到承认,经常用于对痢疾症的管理;Niceritrol已知具有能帮助降低胆固醇水平和改善身体整体脂质特征的特性;该化合物的典型特征是其能够加强脂质新陈代谢,并可能具有防炎特性;就其化学结构而言,Niceritrol具有一种状环,这是许多生物活性化合物中常见的一种运动剂;其药理学影响归因于其在各种代谢途径上的行动,使其成为心血管健康研究的一个对象;与许多药物一样,Niceritro的安全性和功效通过临床研究得到评估,而且对于在治疗中使用其他药物时考虑潜在副作用和与其他药物的相互作用至关重要.

结构式图片

相似化合物

98326-19-3 4591-56-4 614-18-6

合成工艺路线路线简述

    📜季戊四醇,氯化烟碱盐酸盐 以 吡啶 作为反应溶剂,化学反应 5.0H,以97%的收率获得产物季戊四醇四烟酸酯
    参考文献:Gradual Increase In The Dimensionality Of Cobalt And Mercury Coordination Networks Based On Conformation Of Tetradentate Tectons
    标题:Gradual Increase In The Dimensionality Of Cobalt And Mercury Coordination Networks Based On Conformation Of Tetradentate Tectons
    摘要:我们制备了以季戊四醇骨架为基础,分别以四个烟酰基或异烟酰基为配位位点的中性四单齿构造子 1 和 2,并研究了它们在 Hgcl2 或 Cocl2(分别提供 "V "型或方型几何形状的金属酸盐构造子)存在时反应生成配位网络的能力.构造子 1 在同一平面上提供四个配位位点(正方形几何形状),在中性 Hgcl2 的存在下观测到一个 1-D 配位网络,而在 Cocl2 金属酸性构造子的存在下,其四个可用配位位点占据了正方形的四角,从而得到一个 2-D 中性配位网络.对于同样具有四个配位位点但占据假四面体顶点的金属对位体 2,在氯化汞存在下得到的是二维网络,而在氯化钴存在下观测到的是三维网络.在后一种情况下,观测到的是一种两重同源互穿结构.
    DOI:10.1039/b301351K

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-2018370905-A1
    优先权日:2013-04-05
    标题:Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same

    专利号:US-10814013-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:US-10099998-B2
    优先权日:2015-02-04
    标 题 :Compound, and separation method, synthesis method and use thereof
    发明人:DUAN ZHENWEN; GUO SHUREN; LI XUEMEI
    权利人:BEIJING PEKING UNIV WBL BIOTECH CO LTD
    摘要:The invention relates to new compounds as well as a separation method, a synthetic method and use thereof. It is demonstrated by an assay on activity that the compound has an activity of inhibiting an HMG-CoA reductase. In addition, the invention also relates to a derivative of the compound.

    专利号:AU-2007308022-A2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med. 2003 Apr 1;114(5):347-53. Japanese. doi: 10.1007/s10157-010-0333-9. Epub 2010 Sep 15.
    15: Nozaki S, Kihara S, Kubo M, Kameda K, Matsuzawa Y, Tarui S. Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. Int J Clin Pharmacol Ther Toxicol. 1987 Dec;25(12):643-7.

    合成参考文献


    摘要:Oyo Yakuri. Pharmacometrics., 14(741), 1977
    参考文献:10.1046/j.1523-1755.1999.07133.x
    摘要:Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl. 1999 Jul;71():S134–6. doi: 10.1046/j.1523-1755.1999.07133.x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知